12. Referanser

Agilent Technologies (2018). PD-L1 IHC 22C3 pharmDx: Interpretation Manual – NSCLC Santa Clara: Agilent Technologies. Hentet fra https://www.agilent.com/cs/library/usermanuals/public/29158_pd-l1-ihc-22C3-pharmdx-nsclc-interpretation-manual.pdf

Agilent Technologies (2019). PD-L1 IHC 22C3 pharmDx Interpretation Manual – NSCLC: for in Vitro diagnostic use Santa Clara: Agilent Technologies. Hentet fra https://www.agilent.com/cs/library/usermanuals/public/29158_pd-l1-ihc-22C3-pharmdx-nsclc-interpretation-manual.pdf

Ajani, J. A., D'Amico, T. A., Bentrem, D. J., Chao, J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., ... Pluchino, L. A. (2022). Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20(2), 167-192.

Ajani, J. A., D'Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., Denlinger, C. S., Enzinger, P. C., ... Pluchino, L. A. (2019). Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(7), 855-883.

Al-Batran, S., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., Kopp, H., Mayer, F., ... Investigators, F. A. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, 393(10184), 1948-1957.

Al-Batran, S., Homann, N., Schmalenberg, H., Kopp, H., Haag, G. M., Luley, K. B., Schmiegel, W. H., Folprecht, G., ... Hofheinz, R. (2017). Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology, 35(15_suppl), 4004.

Al-Batran, S. E., Goetze, T. O., Mueller, D. W., Vogel, A., Winkler, M., Lorenzen, S., Novotny, A., Pauligk, C., ... Moenig, S. P. (2017). The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer, 17(1), 893.

Al-Batran, S. E., Hartmann, J. T., Hofheinz, R., Homann, N., Rethwisch, V., Probst, S., Stoehlmacher, J., Clemens, M. R., ... Jager, E. (2008). Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Annals of Oncology, 19(11), 1882-7.

Allum, W. H., Stenning, S. P., Bancewicz, J., Clark, P. I., & Langley, R. E. (2009). Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology, 27(30), 5062-7.

Ambiru, S., Miyazaki, M., Ito, H., Nakagawa, K., Shimizu, H., Yoshidome, H., Shimizu, Y., & Nakajima, N. (2001). Benefits and limits of hepatic resection for gastric metastases. American Journal of Surgery, 181(3), 279-83.

Bamias, A., Karina, M., Papakostas, P., Kostopoulos, I., Bobos, M., Vourli, G., Samantas, E., Christodoulou, C., ... Fountzilas, G. (2010). A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemotherapy and Pharmacology, 65(6), 1009-21.

Bang, Y. J., Kim, Y. W., Yang, H. K., Chung, H. C., Park, Y. K., Lee, K. H., Lee, K. W., Kim, Y. H., ... Noh, S. H. (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, 379(9813), 315-21.

Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., ... Kang, Y. K. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742), 687-97.

Barbour, A. P., Rizk, N. P., Gonen, M., Tang, L., Bains, M. S., Rusch, V. W., Coit, D. G., & Brennan, M. F. (2007). Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Annals of Surgery, 246(1), 1-8.

Bartley, A. N., Washington, M. K., Colasacco, C., Ventura, C. B., Ismaila, N., Benson, A. B. ,. 3., Carrato, A., Gulley, M. L., ... Ajani, J. A. (2017). HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. Journal of Clinical Oncology, 35(4), 446-464.

Bedenne, L., Michel, P., Bouche, O., Milan, C., Mariette, C., Conroy, T., Pezet, D., Roullet, B., ... Binquet, C. (2007). Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. Journal of Clinical Oncology, 25(10), 1160-8.

Benitez Majano, S., Di Girolamo, C., Rachet, B., Maringe, C., Guren, M. G., Glimelius, B., Iversen, L. H., Schnell, E. A., ... Walters, S. (2019). Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. The Lancet. Oncology, 20(1), 74-87.

Bergquist, H., Wenger, U., Johnsson, E., Nyman, J., Ejnell, H., Hammerlid, E., Lundell, L., & Ruth, M. (2005). Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Diseases of the Esophagus, 18(3), 131-139.

Beyond TME Collaborative (2013). Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. British Journal of Surgery, 100(8), E1-33.

Bird, T., Michael, M., Bressel, M., Chu, J., Chander, S., Cooray, P., McKendrick, J., Jefford, M., ... Ngan, S. (2017). FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases. Acta Oncologica, 56(5), 646-652.

Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., van Dieren, J. M., Harris, K. L., Hoogerbrugge, N., ... Guilford, P. (2020). Hereditary diffuse gastric cancer: updated clinical practice guidelines. The Lancet. Oncology, 21(8), e386-e397.

Boutin, M., & Gill, S. (2023). Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting. Therapeutic Advances in Medical Oncology, 15, 1.7588359231162576E16.

Bozzetti, F., Bonfanti, G., Bufalino, R., Menotti, V., Persano, S., Andreola, S., Doci, R., & Gennari, L. (1982). Adequacy of margins of resection in gastrectomy for cancer. Annals of Surgery, 196(6), 685-90.

Burgart, L. J., Chopp, W. V., Jain, D. (2021). Protocol for the Examination of Specimens From Patients With Carcinoma of the Pancreas Northfield, IL: College of American Pathologists. Hentet fra https://documents.cap.org/protocols/Panc.Exo_4.2.0.0.REL_CAPCP.pdf

Burmeister, B. H., Dickie, G., Smithers, B. M., Hodge, R., & Morton, K. (2000). Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Archives of Otolaryngology - Head and Neck Surgery, 126(2), 205-8.

Burmeister, B. H., Thomas, J. M., Burmeister, E. A., Walpole, E. T., Harvey, J. A., Thomson, D. B., Barbour, A. P., Gotley, D. C., & Smithers, B. M. (2011). Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. European Journal of Cancer, 47(3), 354-60.

Cai, G., Zhu, J., Hu, W., & Zhang, Z. (2014). Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation: results of a phase II study. Radiation Oncology (London, England), 9, 278.

The Cancer Genome Atlas Research Network (2017). Integrated genomic characterization of oesophageal carcinoma. Nature, 541(7636), 169-175.

Carneiro, F. (2022). Familial and hereditary gastric cancer, an overview. Best Practice & Research: Clinical Gastroenterology, 58-59, 101800.

Cats, A., Jansen, E. P. M., van Grieken, N. C. T., Sikorska, K., Lind, P., Nordsmark, M., Meershoek-Klein Kranenbarg, E., Boot, H., ... Verheij, M. (2018). Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. The Lancet. Oncology, 19(5), 616-628.

Choi, Y. Y., Kim, H., Shin, S. J., Kim, H. Y., Lee, J., Yang, H. K., Kim, W. H., Kim, Y. W., ... Cheong, J. H. (2019). Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Annals of Surgery, 270(2), 309-316.

Coburn, N., Cosby, R., Klein, L., Knight, G., Malthaner, R., Mamazza, J., Mercer, C. D., & Ringash, J. (2018). Staging and surgical approaches in gastric cancer: A systematic review. Cancer Treatment Reviews, 63, 104-115.

Conroy, T., Galais, M., Raoul, J., Bouché, O., Gourgou-Bourgade, S., Douillard, J., Etienne, P., Boige, V., ... Group, U. (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. The Lancet. Oncology, 15(3), 305-314.

Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, J. A. ,. J., Al-Sarraf, M., Byhardt, R., Russell, A. H., ... Leichman, L. L. (1999). Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA, 281(17), 1623-7.

Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., Scarffe, J. H., Lofts, F. J., ... Participants, M. T. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355(1), 11-20.

Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., ... Norman, A. R. (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine, 358(1), 36-46.

Den norske patologforening (2018). Veileder i biopsibesvarelse av maligne svulster (3. utgave (versjon 5.0 – 2018) utg.) [s.l.]: Den norske patologforening. Hentet fra https://www.legeforeningen.no/contentassets/961983a735a24fc5815dff5b3fa1ce01/veileder-i-besvarelse-av-maligne-svulster-2018-versjon-5.pdf

Diaz-Nieto, R., Orti-Rodriguez, R., & Winslet, M. (2013). Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database of Systematic Reviews, (9), CD008415.

Dikken, J. L., Jansen, E. P., Cats, A., Bakker, B., Hartgrink, H. H., Kranenbarg, E. M., Boot, H., Putter, H., ... Verheij, M. (2010). Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. Journal of Clinical Oncology, 28(14), 2430-6.

Dikken, J. L., van Sandick, J. W., Maurits Swellengrebel, H. A., Lind, P. A., Putter, H., Jansen, E. P., Boot, H., van Grieken, N. C., ... Cats, A. (2011). Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer, 11, 329.

Doki, Y., Ajani, J. A., Kato, K., Xu, J., Wyrwicz, L., Motoyama, S., Ogata, T., Kawakami, H., ... Kitagawa, Y. (2022). Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 386(5), 449-462.

Dolan, J. P., Kaur, T., Diggs, B. S., Luna, R. A., Sheppard, B. C., Schipper, P. H., Tieu, B. H., Bakis, G., ... Hunter, J. G. (2016). Significant understaging is seen in clinically staged T2N0 esophageal cancer patients undergoing esophagectomy. Diseases of the Esophagus, 29(4), 320-325.

Earle, C. C., & Maroun, J. A. (1998). Adjuvant chemotherapy after curative resection for gastric cancer: revisiting a meta-analysis of randomised trials. Proceedings of the American Society of Clinical Oncology, 17, 263a.

Elsherif, S. B., Andreou, S., Virarkar, M., Soule, E., Gopireddy, D. R., Bhosale, P. R., & Lall, C. (2020). Role of precision imaging in esophageal cancer. Journal of Thoracic Disease, 12(9), 5159-5176.

Enzinger, P. C., Burtness, B. A., Niedzwiecki, D., Ye, X., Douglas, K., Ilson, D. H., Villaflor, V. M., Cohen, S. J., ... Goldberg, R. M. (2016). CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal of Clinical Oncology, 34(23), 2736-2742.

Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., Bray, F. (2022). Global Cancer Observatory: Cancer Today.. Lyon, France: International Agency for Research on Cancer. Hentet 19. mai 2026 fra https://gco.iarc.fr/today

Fitzgerald, R. C., Hardwick, R., Huntsman, D., Carneiro, F., Guilford, P., Blair, V., Chung, D. C., Norton, J., ... Caldas, C. (2010). Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 47(7), 436-44.

Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., ... Yoon, H. H. (2018). Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol, 4(5), e180013.

Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., ... Tabernero, J. (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 383(9911), 31-9.

Fujitani, K., Yang, H. K., Mizusawa, J., Kim, Y. W., Terashima, M., Han, S. U., Iwasaki, Y., Hyung, W. J., ... Tsujinaka, T. (2016). Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. The Lancet. Oncology, 17(3), 309-18.

Gkika, E., Gauler, T., Eberhardt, W., Stahl, M., Stuschke, M., & Pottgen, C. (2014). Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. Diseases of the Esophagus, 27(7), 678-84.

Goense, L., Meziani, J., Borggreve, A. S., van Rossum, P. S., Meijer, G. J., Ruurda, J. P., van Hillegersberg, R., & Weusten, B. L. (2018). Role of adjuvant chemoradiotherapy after endoscopic treatment of early-stage esophageal cancer: a systematic review. Minerva Chirurgica, 73(4), 428-436.

Goense, L., van Rossum, P. S., Reitsma, J. B., Lam, M. G., Meijer, G. J., van Vulpen, M., Ruurda, J. P., & van Hillegersberg, R. (2015). Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis. Journal of Nuclear Medicine, 56(7), 995-1002.

Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., Andre, T., Gornet, J. M., Aparicio, T., ... Bouche, O. (2014). Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. Journal of Clinical Oncology, 32(31), 3520-6.

Hallissey, M. T., Jewkes, A. J., Dunn, J. A., Ward, L., & Fielding, J. W. (1993). Resection-line involvement in gastric cancer: a continuing problem. British Journal of Surgery, 80(11), 1418-20.

Hansford, S., Kaurah, P., Li-Chang, H., Woo, M., Senz, J., Pinheiro, H., Schrader, K. A., Schaeffer, D. F., ... Huntsman, D. G. (2015). Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol, 1(1), 23-32.

Hauge, T., & Larssen, L. (2023). Endoskopisk behandling av ventrikkelcancer. Kirurgen, (1), 16-17.

Haugstvedt, T., Viste, A., Eide, G. E., & Söreide, O. (1989). The survival benefit of resection in patients with advanced stomach cancer: the Norwegian multicenter experience. Norwegian Stomach Cancer Trial. World Journal of Surgery, 13(5), 617-21; discussion 621-2.

Helsedirektoratet (2023). Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft Oslo: Helsedirektoratet. Hentet fra https://www.helsebiblioteket.no/innhold/nasjonal-faglig-retningslinje/brystkreft-handlingsprogram

Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., ... Hyodo, I. (2013). Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology, 31(35), 4438-4444.

Hoeppner, J., Brunner, T., Schmoor, C., Bronsert, P., Kulemann, B., Claus, R., Utzolino, S., Izbicki, J. R., ... Lordick, F. (2025). Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. New England Journal of Medicine, 392(4), 323-335.

Hofheinz, R. D., Merx, K., Haag, G. M., Springfeld, C., Ettrich, T., Borchert, K., Kretzschmar, A., Teschendorf, C., ... Al-Batran, S. E. (2022). FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. Journal of Clinical Oncology, 40(32), 3750-3761.

Hofmann, M., Stoss, O., Shi, D., Buttner, R., van de Vijver, M., Kim, W., Ochiai, A., Ruschoff, J., & Henkel, T. (2008). Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 52(7), 797-805.

Homs, M. Y., Steyerberg, E. W., Eijkenboom, W. M., Tilanus, H. W., Stalpers, L. J., Bartelsman, J. F., van Lanschot, J. J., Wijrdeman, H. K., ... Siersema, P. D. (2004). Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet, 364(9444), 1497-504.

Homs, M. Y., Steyerberg, E. W., Eijkenboom, W. M., Tilanus, H. W., Stalpers, L. J., Bartelsman, J. F., van Lanschot, J. J., Wijrdeman, H. K., ... Siersema, P. D. (2005). Palliatieve behandeling voor slokdarmkanker met passageklachten: gunstiger uitkomsten van eenmalige inwendige brachytherapie dan van plaatsing van een zelfexpanderende stent; multicentrisch, gerandomiseerd onderzoek [Palliative treatment of esophageal cancer with dysphagia: more favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study]. Nederlands Tijdschrift voor Geneeskunde, 149(50), 2800-2806 [På nederlandsk].

Huang, F. L., & Yu, S. J. (2018). Esophageal cancer: Risk factors, genetic association, and treatment. Asian Journal of Surgery, 41(3), 210-215.

Huang, S. H., Lockwood, G., Brierley, J., Cummings, B., Kim, J., Wong, R., Bayley, A., & Ringash, J. (2008). Effect of concurrent high-dose cisplatin chemotherapy and conformal radiotherapy on cervical esophageal cancer survival. International Journal of Radiation Oncology, Biology, Physics, 71(3), 735-40.

Hulshof, M., Geijsen, E. D., Rozema, T., Oppedijk, V., Buijsen, J., Neelis, K. J., Nuyttens, J., van der Sangen, M. J. C., ... van der Gaast, A. (2021). Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). Journal of Clinical Oncology, 39(25), 2816-2824.

International Agency for Research on Cancer/World Health Organization (2022). Kreft hos menneske: kjente årsaker og forebyggende tiltak etter kreftform. IARCs monografier for identifisering av kreftfremkallende påvirkning hos mennesker og IARCs håndbøker for kreftforebygging [plakat]. Lyon: IARC. Hentet fra https://monographs.iarc.who.int/wp-content/uploads/2023/05/OrganSitePoster.PlusHandbooks.Norwegian.18102022.pdf

Janjigian, Y. Y., Al-Batran, S. E., Wainberg, Z. A., Muro, K., Molena, D., Van Cutsem, E., Hyung, W. J., Wyrwicz, L., ... Tabernero, J. (2025). Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. New England Journal of Medicine, 393(3), 217-230.

Janjigian, Y. Y., Al-Batran, S. E., Wainberg, Z. A., Van Cutsem, E., Molena, D., Muro, K., Hyung, W. J., Wyrwicz, L. S., ... Tabernero, J. (2023). LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Annals of Oncology, 34(Suppl 2), S1315-S1316.

Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J. P., Yanez, P., Wyrwicz, L. S., ... Rha, S. Y. (2023). Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet, 402(10418), 2197–2208.

Janjigian, Y. Y., Shitara, K., Ajani, J. A., Shen, L., Garrido, M., Gallardo, C., Wyrwicz, L., Yamaguchi, K., ... Moehler, M. (2026). Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. Annals of Oncology, 37, 787-97.

Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., ... Ajani, J. A. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet, 398(10294), 27-40.

Japanese Gastric Cancer Association (2023). Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer, 26(1), 1-25.

Jeurnink, S. M., Steyerberg, E. W., Hof, G., van Eijck, C. H., Kuipers, E. J., & Siersema, P. D. (2007). Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients. Journal of Surgical Oncology, 96(5), 389-96.

Kamarajah, S. K., Phillips, A. W., Griffiths, E. A., Ferri, L., Hofstetter, W. L., & Markar, S. R. (2021). Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis. Annals of Surgical Oncology, 28(13), 8485-8494.

Kang, Y. K., Boku, N., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., Chung, H. C., Chen, J. S., ... Chen, L. T. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390(10111), 2461-2471.

Kato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C. Y., Chin, K., Kadowaki, S., Ahn, M. J., ... Kitagawa, Y. (2019). Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology, 20(11), 1506-1517.

Kato, K., Machida, R., Ito, Y., Daiko, H., Ozawa, S., Ogata, T., Hara, H., Kojima, T., ... Kitagawa, Y. (2024). Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet, 404(10447), 55-66.

Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Cutsem, E. V., Piessen, G., Mendez, G., Feliciano, J. L., ... Moehler, M. H. (2025). Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577. Journal of Clinical Oncology, 43(16 suppl), 4000.

Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., ... Moehler, M. (2021). Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. New England Journal of Medicine, 384(13), 1191-1203.

Kidane, B., Coughlin, S., Vogt, K., & Malthaner, R. (2015). Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database of Systematic Reviews, 5, CD001556.

Klevebro, F., Alexandersson von Dobeln, G., Wang, N., Johnsen, G., Jacobsen, A. B., Friesland, S., Hatlevoll, I., Glenjen, N. I., ... Nilsson, M. (2016). A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Annals of Oncology, 27(4), 660-7.

Kohn, G. P., Litle, V., Eliya, Y., Leng, S., Asghari-Jafarabadi, M., Contreras, N., Davies, A., Lackner, R., ... Griffiths, E. A. (2026). ISDE guidelines on the management of cT2N0 esophageal cancer. Diseases of the Esophagus, 39(2), doag019.

Kojima, T., Shah, M. A., Muro, K., Francois, E., Adenis, A., Hsu, C. H., Doi, T., Moriwaki, T., ... Metges, J. P. (2020). Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology, 38(35), 4138-4148.

Komeda, K., Hayashi, M., Kubo, S., Nagano, H., Nakai, T., Kaibori, M., Wada, H., Takemura, S., ... Uchiyama, K. (2014). High survival in patients operated for small isolated liver metastases from gastric cancer: a multi-institutional study. World Journal of Surgery, 38(10), 2692-7.

Kranzfelder, M., Schuster, T., Geinitz, H., Friess, H., & Buchler, P. (2011). Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. British Journal of Surgery, 98(6), 768-83.

Kreftregisteret (2022). Kreftregisterets statistikkbank v1.2. [database]. Oslo: Kreftregisteret. Hentet 29.01.2024 fra https://sb.kreftregisteret.no

Kumagai, K., Rouvelas, I., Ernberg, A., Persson, S., Analatos, A., Mariosa, D., Lindblad, M., Nilsson, M., ... Tsai, J. A. (2016). A systematic review and meta-analysis comparing partial stomach partitioning gastrojejunostomy versus conventional gastrojejunostomy for malignant gastroduodenal obstruction. Langenbecks Archives of Surgery, 401(6), 777-85.

Kurokawa, Y., Doki, Y., Mizusawa, J., Terashima, M., Katai, H., Yoshikawa, T., Kimura, Y., Takiguchi, S., ... Sasako, M. (2018). Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. The Lancet. Gastroenterology & Hepatology, 3(7), 460-468.

Kurokawa, Y., Takeuchi, H., Doki, Y., Mine, S., Terashima, M., Yasuda, T., Yoshida, K., Daiko, H., ... Kitagawa, Y. (2021). Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Annals of Surgery, 274(1), 120-127.

Kwee, R. M., & Kwee, T. C. (2007). Imaging in local staging of gastric cancer: a systematic review. Journal of Clinical Oncology, 25(15), 2107-16.

Kwon, H. C., Kim, M. C., Kim, K. H., Jang, J. S., Oh, S. Y., Kim, S. H., Kwon, K. A., Lee, S., ... Kim, H. J. (2010). Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia-Pacific Journal of Clinical Oncology, 6(4), 278-85.

Lai, A., Lipka, S., Kumar, A., Sethi, S., Bromberg, D., Li, N., Shen, H., Stefaniwsky, L., & Brady, P. (2018). Role of Esophageal Metal Stents Placement and Combination Therapy in Inoperable Esophageal Carcinoma: A Systematic Review and Meta-analysis. Digestive Diseases and Sciences, 63(4), 1025-1034.

Larsen, I. K., Aagnes, B., Breivik, S., Hestad, J. J., Jakobsen, E., Johannesen, T. B., ... Lambert, P. C. (2026). Cancer in Norway 2025 - Cancer incidence, mortality, survival and prevalence in Norway Oslo: Norwegian Institute of Public Health, Cancer Registry of Norway. Hentet fra https://www.fhi.no/publ/2026/cancer-in-norway-2025/

Larssen, L., Medhus, A. W., Hjermstad, M. J., Korner, H., Glomsaker, T., Soberg, T., Gleditsch, D., Hovde, O., ... Hauge, T. (2011). Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian multicenter study. Surgical Endoscopy, 25(10), 3162-9.

Leong, T., Smithers, B. M., Haustermans, K., Michael, M., Gebski, V., Miller, D., Zalcberg, J., Boussioutas, A., ... Wong, R. (2017). TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 24(8), 2252-2258.

Leong, T., Smithers, B. M., Michael, M., Gebski, V., Boussioutas, A., Miller, D., Simes, J., Zalcberg, J., ... Wong, R. (2015). TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer, 15, 532.

Levard, H., Pouliquen, X., Hay, J. M., Fingerhut, A., Langlois-Zantain, O., Huguier, M., Lozach, P., & Testart, J. (1998). 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. European Journal of Surgery, 164(11), 849-57.

Liu, C., Fang, F., Kong, Y., & ElGabry, E. A. (2023). Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. Diagnostic Pathology, 18(1), 48.

Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., Vogel, A., & Smyth, E. C. (2022). Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 33(10), 1005-1020.

Lordick, F., Kang, Y. K., Chung, H. C., Salman, P., Oh, S. C., Bodoky, G., Kurteva, G., Volovat, C., ... Moehler, M. (2013). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. The Lancet. Oncology, 14(6), 490-9.

Lorenzen, S., Götze, T. O., Thuss-Patience, P., Biebl, M., Homann, N., Schenk, M., Lindig, U., Heuer, V., ... Al-Batran, S. E. (2023). Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. Journal of Clinical Oncology, , Jco2300975.

Lu, Z., Fang, Y., Liu, C., Zhang, X., Xin, X., He, Y., Cao, Y., Jiao, X., ... Shen, L. (2021). Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. Journal of Clinical Oncology, 39(7), 748-756.

Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., ... Martenson, J. A. (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine, 345(10), 725-30.

Mala, T., Førland, D. T., Vetti, H. H., Skagemo, C. U., Johannessen, H. O., & Johnson, E. (2020). Gastrisk adenokarsinom og proksimal ventrikkelpolypose – en sjelden form for arvelig magesekkreft. Tidsskrift for den Norske Legeforening, 140(7)

Malthaner, R. A., Collin, S., & Fenlon, D. (2006). Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database of Systematic Reviews, (3), CD001556.

Mantziari, S., St Amour, P., Abboretti, F., Teixeira-Farinha, H., Gaspar Figueiredo, S., Gronnier, C., Schizas, D., Demartines, N., & Schäfer, M. (2023). A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma. Cancers, 15(5)

Mariette, C., Dahan, L., Mornex, F., Maillard, E., Thomas, P. A., Meunier, B., Boige, V., Pezet, D., ... Seitz, J. F. (2014). Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. Journal of Clinical Oncology, 32(23), 2416-22.

Markar, S. R., Gronnier, C., Pasquer, A., Duhamel, A., Beal, H., Théreaux, J., Gagnière, J., Lebreton, G., ... AFC, F. w. g. –. F. –. (2016). Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. European Journal of Cancer, 56, 59-68.

Martella, L., Bertozzi, S., Londero, A. P., Steffan, A., De Paoli, P., & Bertola, G. (2015). Surgery for Liver Metastases From Gastric Cancer: A Meta-Analysis of Observational Studies. Medicine (Baltimore), 94(31), e1113.

Martin, R. C. ,. 2., Jaques, D. P., Brennan, M. F., & Karpeh, M. (2002). Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection?. Journal of the American College of Surgeons, 194(5), 568-77.

Matsuda, S., Takeuchi, H., Kawakubo, H., & Kitagawa, Y. (2017). Three-field lymph node dissection in esophageal cancer surgery. Journal of Thoracic Disease, 9(Suppl 8), S731-s740.

Meining, A., Rösch, T. (2024). Paris Classification Early Cancer. [nettdokument]. Munich: Endoscopy Campus. Hentet 07.06.2024 fra https://www.endoscopy-campus.com/en/classifications/paris-classification-early-cancer/

Minsky, B. D., Pajak, T. F., Ginsberg, R. J., Pisansky, T. M., Martenson, J., Komaki, R., Okawara, G., Rosenthal, S. A., & Kelsen, D. P. (2002). INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. Journal of Clinical Oncology, 20(5), 1167-74.

Mota, F. C., Cecconello, I., Takeda, F. R., Tustumi, F., Sallum, R. A. A., & Bernardo, W. M. (2018). Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options. International Journal of Surgery (London, England), 54(Pt A), 176-181.

Münch, S., Pigorsch, S. U., Dapper, H., Weichert, W., Friess, H., Braren, R., Combs, S. E., ... Habermehl, D. (2018). Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiation Oncology (London, England), 13(1), 139.

Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B. C., Nor, I. M., ... Douillard, J. Y. (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology, 30(1), 34-43.

Niclauss, N., Jung, M. K., Chevallay, M., & Mönig, S. P. (2019). Minimal length of proximal resection margin in adenocarcinoma of the esophagogastric junction: a systematic review of the literature. Updates in Surgery, 71(3), 401-409.

Nilsson, M., Olafsdottir, H., Alexandersson von Döbeln, G., Villegas, F., Gagliardi, G., Hellström, M., Wang, Q. L., Johansson, H., ... Lordick, F. (2022). Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. Frontiers in Oncology, 12, 917961.

Noh, S. H., Park, S. R., Yang, H. K., Chung, H. C., Chung, I. J., Kim, S. W., Kim, H. H., Choi, J. H., ... Bang, Y. J. (2014). Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. The Lancet. Oncology, 15(12), 1389-96.

Noordzij, I. C., Curvers, W. L., & Schoon, E. J. (2019). Endoscopic resection for early esophageal carcinoma. Journal of Thoracic Disease, 11(Supplement5), S713-S722.

Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., ... Kang, Y. K. (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology, 29(30), 3968-76.

Okano, K., Maeba, T., Ishimura, K., Karasawa, Y., Goda, F., Wakabayashi, H., Usuki, H., & Maeta, H. (2002). Hepatic resection for metastatic tumors from gastric cancer. Annals of Surgery, 235(1), 86-91.

Owens, R., Cox, C., Gomberg, S., Pan, S., Radhakrishna, G., Parikh, S., Goody, R., Hingorani, M., ... Mukherjee, S. (2020). Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. Clinical Oncology (Royal College of Radiologists), 32(2), 121-130.

Pacelli, F., Cusumano, G., Rosa, F., Marrelli, D., Dicosmo, M., Cipollari, C., Marchet, A., Scaringi, S., ... Doglietto, G. B. (2013). Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. JAMA Surg, 148(4), 353-60.

Paoletti, X., Oba, K., Burzykowski, T., Michiels, S., Ohashi, Y., Pignon, J. P., Rougier, P., Sakamoto, J., ... Buyse, M. (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 303(17), 1729-37.

Pasquali, S., Yim, G., Vohra, R. S., Mocellin, S., Nyanhongo, D., Marriott, P., Geh, J. I., & Griffiths, E. A. (2017). Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis. Annals of Surgery, 265(3), 481-491.

Patel, C. M., Sahdev, A., & Reznek, R. H. (2011). CT, MRI and PET imaging in peritoneal malignancy. Cancer Imaging, 11(1), 123-39.

Pech, O., Bollschweiler, E., Manner, H., Leers, J., Ell, C., & Hölscher, A. H. (2011). Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Annals of Surgery, 254(1), 67-72.

Pietrantonio, F., Miceli, R., Raimondi, A., Kim, Y. W., Kang, W. K., Langley, R. E., Choi, Y. Y., Kim, K. M., ... Smyth, E. C. (2019). Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 37(35), 3392-3400.

Pimentel-Nunes, P., Libânio, D., Bastiaansen, B. A. J., Bhandari, P., Bisschops, R., Bourke, M. J., Esposito, G., Lemmers, A., ... Dinis-Ribeiro, M. (2022). Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. Endoscopy, 54(6), 591-622.

Qiu, M. Z., Oh, D. Y., Kato, K., Arkenau, T., Tabernero, J., Correa, M. C., Zimina, A. V., Bai, Y., ... Xu, R. H. (2024). Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ (Clinical research ed.), 385, e078876.

Raimondi, A., Lonardi, S., Murgioni, S., Cardellino, G. G., Tamberi, S., Strippoli, A., Palermo, F., De Manzoni, G., ... Pietrantonio, F. (2025). Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. Annals of Oncology, 36(3), 285-296.

Reynolds, J. V., Preston, S. R., O'Neill, B., Lowery, M. A., Baeksgaard, L., Crosby, T., Cunningham, M., Cuffe, S., ... Power, D. (2023). Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. The Lancet. Gastroenterology & Hepatology, 8(11), 1015-1027.

Rice, T. W., Ishwaran, H., Ferguson, M. K., Blackstone, E. H., & Goldstraw, P. (2017). Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer. Journal of Thoracic Oncology, 12(1), 36-42.

Ronellenfitsch, U., Schwarzbach, M., Hofheinz, R., Kienle, P., Kieser, M., Slanger, T. E., Burmeister, B., Kelsen, D., ... Jensen, K. (2013). Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. European Journal of Cancer, 49(15), 3149-58.

Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., ... Norman, A. (2002). Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. Journal of Clinical Oncology, 20(8), 1996-2004.

Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., ... Arai, K. (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New England Journal of Medicine, 357(18), 1810-20.

Samson, P., Puri, V., Robinson, C., Lockhart, C., Carpenter, D., Broderick, S., Kreisel, D., Krupnick, A. S., ... Crabtree, T. (2016). Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy. Annals of Thoracic Surgery, 101(6), 2102-2111.

Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., Nashimoto, A., Fujii, M., ... Ohashi, Y. (2011). Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of Clinical Oncology, 29(33), 4387-93.

Schena, C. A., Laterza, V., De Sio, D., Quero, G., Fiorillo, C., Gunawardena, G., Strippoli, A., Tondolo, V., ... Rosa, F. (2023). The Role of Staging Laparoscopy for Gastric Cancer Patients: Current Evidence and Future Perspectives. Cancers, 15(13)

Sgourakis, G., Gockel, I., Radtke, A., Dedemadi, G., Goumas, K., Mylona, S., Lang, H., Tsiamis, A., & Karaliotas, C. (2010). The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes. Digestive Diseases and Sciences, 55(11), 3018-30.

Shah, M. A., Bennouna, J., Doi, T., Shen, L., Kato, K., Adenis, A., Mamon, H. J., Moehler, M., ... Enzinger, P. (2021). KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncology, 17(10), 1143-1153.

Shah, M. A., Shitara, K., Ajani, J. A., Bang, Y. J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., ... Xu, R. H. (2023). Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nature Medicine, 29(8), 2133-2141.

Shapiro, J., van Lanschot, J. J. B., Hulshof, M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., ... van der Gaast, A. (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet. Oncology, 16(9), 1090-1098.

Shitara, K., Bang, Y. J., Iwasa, S., Sugimoto, N., Ryu, M. H., Sakai, D., Chung, H. C., Kawakami, H., ... Yamaguchi, K. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine, 382(25), 2419-2430.

Shitara, K., Lordick, F., Bang, Y. J., Enzinger, P., Ilson, D., Shah, M. A., Van Cutsem, E., Xu, R. H., ... Ajani, J. A. (2023). Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet, 401(10389), 1655-1668.

Shitara, K., Rha, S. Y., Wyrwicz, L. S., Oshima, T., Karaseva, N., Osipov, M., Yasui, H., Yabusaki, H., ... Bang, Y. (2024). Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. The Lancet. Oncology, 25(2), 212-224.

Shitara, K., Van Cutsem, E., Lonardi, S., Coutzac, C., Dekervel, J., Hochhauser, D., Shen, L., Mansoor, W., ... Pietrantonio, F. (2025). Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. New England Journal of Medicine, 393(4), 336-348.

Singh, M., Low, D. E., & Maynard, N. D. (2023). Left thoracoabdominal oesophagectomy: contemporary update on technique and outcomes. British Journal of Surgery, 110(12), 1574-1587.

Sjoquist, K. M., Burmeister, B. H., Smithers, B. M., Zalcberg, J. R., Simes, R. J., Barbour, A., & Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet. Oncology, 12(7), 681-92.

Smalley, S. R., Benedetti, J. K., Haller, D. G., Hundahl, S. A., Estes, N. C., Ajani, J. A., Gunderson, L. L., Goldman, B., ... Macdonald, J. S. (2012). Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. Journal of Clinical Oncology, 30(19), 2327-33.

Smyth, E. C., Wotherspoon, A., Peckitt, C., Gonzalez, D., Hulkki-Wilson, S., Eltahir, Z., Fassan, M., Rugge, M., ... Cunningham, D. (2017). Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol, 3(9), 1197-1203.

Songun, I., Putter, H., Kranenbarg, E. M., Sasako, M., & van de Velde, C. J. (2010). Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet. Oncology, 11(5), 439-49.

Speicher, P. J., Ganapathi, A. M., Englum, B. R., Hartwig, M. G., Onaitis, M. W., D'Amico, T. A., & Berry, M. F. (2014). Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. Journal of Thoracic Oncology, 9(8), 1195-1201.

Stahl, M., Stuschke, M., Lehmann, N., Meyer, H., Walz, M. K., Seeber, S., Klump, B., Budach, W., ... Wilke, H. (2005). Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus. Journal of Clinical Oncology, 23(10), 2310-2317.

Stahl, M., Walz, M. K., Stuschke, M., Lehmann, N., Meyer, H. J., Riera-Knorrenschild, J., Langer, P., Engenhart-Cabillic, R., ... Wilke, H. (2009). Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Journal of Clinical Oncology, 27(6), 851-6.

Steber, C., Hughes, R. T., McTyre, E. R., Soike, M., Farris, M., Levine, B. J., Pasche, B., Levine, E., & Blackstock, A. W. (2021). Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. Cureus, 13(1), e12574.

Stiekema, J., Trip, A. K., Jansen, E. P., Boot, H., Cats, A., Ponz, O. B., Verheij, M., & van Sandick, J. W. (2014). The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Annals of Surgical Oncology, 21(4), 1107-14.

Stockeld, D., Tennvall, J., Wagenius, G., Albertsson, M., Backman, L., Brodin, O., Cwikiel, M., Granstrom, L., ... Fagerberg, J. (2001). A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus. Acta Oncologica, 40(5), 566-73.

Subasinghe, D., Acott, N., & Kumarasinghe, M. P. (2019). A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma. Gastrointestinal Endoscopy, 90(1), 44-54.

Søreide, J. A., Greve, O. J., Gudlaugsson, E., & Størset, S. (2016). Hepatoid adenocarcinoma of the stomach--proper identification and treatment remain a challenge. Scandinavian Journal of Gastroenterology, 51(6), 646-53.

Tabernero, J., Al-Batran, S. E., Wainberg, Z. A. A., Muro, K., Molena, D., Van Cutsem, E., Hyung, W. J., Wyrwicz, L. S., ... Janjigian, Y. Y. (2025). LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma. Annals of Oncology, 36(Suppl 2), S1623-S1624.

Ter Veer, E., Haj Mohammad, N., van Valkenhoef, G., Ngai, L. L., Mali, R. M. A., Anderegg, M. C., van Oijen, M. G. H., & van Laarhoven, H. W. M. (2016). The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. Journal of the National Cancer Institute, 108(10)

Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., ... Reichardt, P. (2011). Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer, 47(15), 2306-14.

Ueda, K., Iwahashi, M., Nakamori, M., Nakamura, M., Naka, T., Ishida, K., Ojima, T., & Yamaue, H. (2009). Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Archives of Surgery, 394(4), 647-53.

Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., ... Ajani, J. A. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology, 24(31), 4991-7.

van der Wilk, B. J., Eyck, B. M., Wijnhoven, B. P. L., Lagarde, S. M., Rosman, C., Noordman, B. J., Valkema, M. J., Coene, P. -., ... van Lanschot, J. (2023). Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial. Annals of Oncology, 34(Suppl 2), S1317.

van Hagen, P., Hulshof, M. C., van Lanschot, J. J., Steyerberg, E. W., van Berge Henegouwen, M. I., Wijnhoven, B. P., Richel, D. J., Nieuwenhuijzen, G. A., ... van der Gaast, A. (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine, 366(22), 2074-84.

van Ruler, M. A. P., Peters, F. P., Slingerland, M., Fiocco, M., Grootenboers, D. A. R. H., Vulink, A. J. E., Marijnen, C. A. M., & Neelis, K. J. (2017). Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer. Diseases of the Esophagus, 30(4), 1-9.

van Velzen, M. J. M., Derks, S., van Grieken, N. C. T., Haj Mohammad, N., & van Laarhoven, H. W. M. (2020). MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treatment Reviews, 86, 102024.

von Döbeln, G. A., Klevebro, F., Jacobsen, A. B., Johannessen, H. O., Nielsen, N. H., Johnsen, G., Hatlevoll, I., Glenjen, N. I., ... Nilsson, M. (2019). Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. Diseases of the Esophagus, 32(2), 10.1093/dote/doy078.

Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A. F., Okines, C., Wotherspoon, A., Saffery, C., ... Barbachano, Y. (2013). Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. The Lancet. Oncology, 14(6), 481-9.

Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2014). Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. European Journal of Surgical Oncology, 40(5), 584-91.

Wagner, A. D., Grabsch, H. I., Mauer, M., Romario, U. F., Kang, Y., Bouche, O., Lorenzen, S., Moehler, M. H., ... Lordick, F. (2023). Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group. Journal of Clinical Oncology, 41(16_suppl), 4057-4057.

Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B., Ho, J., & Unverzagt, S. (2017). Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews, 8(8), CD004064.

Walterbos, N. R., Fiocco, M., Neelis, K. J., van der Linden, Y. M., Langers, A. M. J., Slingerland, M., de Steur, W. O., Peters, F. P., & Lips, I. M. (2019). Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer. Clinical and Translational Radiation Oncology, 17, 24-31.

Wang, Z. X., Cui, C., Yao, J., Zhang, Y., Li, M., Feng, J., Yang, S., Fan, Y., ... Wang, F. (2022). Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell, 40(3), 277-288.e3.

Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., ... Meehan, M. (1997). Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology, 15(1), 261-267.

Welsh, J., Settle, S. H., Amini, A., Xiao, L., Suzuki, A., Hayashi, Y., Hofstetter, W., Komaki, R., ... Ajani, J. A. (2012). Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer, 118(10), 2632-40.

WHO Classification of Tumours Editorial Board (2019). Digestive System Tumours (WHO Classification of Tumours, 5th Edition, Volume 1). Geneva: World Health Organization.

Wilke, H., Muro, K., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., ... Ohtsu, A. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet. Oncology, 15(11), 1224-35.

World Cancer Research Fund/American Institute for Cancer Research (2018). Diet, Nutrition, Physical Activity and Cancer: a Global Perspective London: World Cancer Research Fund/American Institute for Cancer Research. Hentet fra https://www.wcrf.org/wp-content/uploads/2021/02/oesophageal-cancer-report.pdf

Xu, Y., Yu, X., Chen, Q., & Mao, W. (2012). Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?. World Journal of Surgical Oncology, 10, 173.

Xu, Y. J., Zhu, W. G., Liao, Z. X., Kong, Y., Wang, W. W., Li, J. C., Huang, R., He, H., ... Chen, M. (2020). [A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma]. Zhonghua Yi Xue Za Zhi, 100(23), 1783-1788 [På kinesisk].

Yamamoto, S., Kawakami, H., Kii, T., Hara, H., Kawabata, R., Kawada, J., Takeno, A., Matsuyama, J., ... Satoh, T. (2021). Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. European Journal of Cancer, 154, 307-315.

Ychou, M., Boige, V., Pignon, J. P., Conroy, T., Bouche, O., Lebreton, G., Ducourtieux, M., Bedenne, L., ... Rougier, P. (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology, 29(13), 1715-21.

Ye, T., Sun, Y., Zhang, Y., Zhang, Y., & Chen, H. (2013). Three-field or two-field resection for thoracic esophageal cancer: a meta-analysis. Annals of Thoracic Surgery, 96(6), 1933-41.

Zenda, S., Kojima, T., Kato, K., Izumi, S., Ozawa, T., Kiyota, N., Katada, C., Tsushima, T., ... Daiko, H. (2016). Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus. International Journal of Radiation Oncology, Biology, Physics, 96(5), 976-984.